Supplement Forms/Alternate Names:

  • N-Acetyl-5-Methoxytryptamine
  • 5-Methoxy-N-Acetyltryptamine

Introduction

Melatonin is a hormone made by the body that helps regulate sleep. It can be taken as a pill, powder, or extract. It can also be applied to the skin and injected into the bloodstream by a healthcare provider. Melatonin has been used to ease anxiety, improve sleep, and lower blood pressure.

Dosages

1 to 10 milligrams as needed

What Research Shows

Likely Effective

May Not Be Effective

Unlikely to Be Effective

Not Enough Data to Assess

Editorial process and description of evidence categories can be found at EBSCO NAT Editorial Process.

Editorial process and description of evidence categories can be found at EBSCO NAT Editorial Process.

Safety Notes

It is likely safe to take melatonin in small doses for a short time, but headache and daytime drowsiness may happen. Not enough studies have been done to say whether it is safe to take for a long period. It is also not known whether it is safe to take by women who are pregnant, trying to become pregnant, or breastfeeding.

Interactions

Talk to your doctor about any supplements or therapy you would like to use. Some can interfere with treatment or make conditions worse, such as:

  • Melatonin contains lactose. People with problems digesting lactose should talk to their doctors before taking melatonin.
  • People who have liver problems, immune diseases, kidney problems, or neurological problems should talk to their doctor before taking melatonin.

References

REFA Alzheimer Disease

REFA1 McCleery J, Cohen DA, et al. Pharmacotherapies for sleep disturbances in Alzheimer's disease. Cochrane Database Syst Rev. 2014 Mar 21;(3):CD009178.

REFA2 Xu J, Wang LL, et al. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2015 Aug;30(5):439-447.

REFA3 McCleery J, Cohen DA, et al. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2016 Nov 16;11:CD009178.

REFA4 Zhang W, Chen XY, et al. Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol Sci. 2016;37(1):57-65.

REFA5 Wang YY, Zheng W, et al. Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer’s disease. Int J Geriatr Psychiatry. 2017;32(1):50-57.

REFB Anxiety

REFB1 Hansen MV, Halladin NL, et al. Melatonin for pre- and postoperative anxiety in adults. Cochrane Database Syst Rev. 2015;(4):CD009861.

REFC Autism Spectrum Disorders

REFC1 Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol. 2011;53(9):783-792.

REFD Cancer Treatment Support

REFD1 Seely D, Wu P, et al. Melatonin as adjuvant care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 2012;11(4):293-303.

REFD2 Wang YM, Jin BZ, et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol. 2012 May;69(5):1213-1220.

REFE Delirium

REFE1 Siddiqi N, Harrison JK, Clegg A, Teale EA, Young J, Taylor J, Simpkins SA. Interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2016 Mar 11;3:CD005563.

REFE2 Chen S, Shi L, et al. Exogenous Melatonin for Delirium Prevention: a Meta-analysis of Randomized Controlled Trials. Mol Neurobiol. 2016 Aug;53(6):4046-4053.

REFF Depression

REFF1 Hansen MV, Danielsen AK, et al. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2014 Nov;24(11):1719-1728.

REFG Dysmenorrhea

REFG1 Pattanittum P, Kunyanone N, et al. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev. 2016 Mar 22;3:CD002124.

REFH Emergence Agitation After General Anesthesia

REFH1 Andersen LP, Werner MU, et al. A systematic review of peri-operative melatonin. Anaesthesia. 2014 Oct;69(10):1163-71.

REFH2 Mihara T, Nakamura N, et al. Effects of melatonin premedication to prevent emergence agitation after general anaesthesia in children: A systematic review and meta-analysis with trial sequential analysis. Eur J Anaesthesiol. 2015 Dec;32(12):862-871.

REFI Epilepsy

REFI1 Brigo F, Igwe SC, et al. Melatonin as add-on treatment for epilepsy. Cochrane Database Syst Rev. 2016;(8):CD006967.

REFJ High Blood Pressure

REFJ1 Grossman E, Laudon M, et al. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag. 2011;7:577-584.

REFJ2 Hadi A, Ghaedi E, et al. Effects of Melatonin Supplementation On Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Horm Metab Res. 2019 Mar;51(3):157-164.

REFK Jet Lag

REFK1 Tortorlo F, Farren F, et al. Is melatonin useful for jet lag? Medwave. 2015;15(3):e6343.

REFL Metabolic Disorders

REFL1 Doosti-Irani A, Ostadohammadi V, et al. The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Horm Metab Res. 2018;50(11):783-790.

REFM Migraine

REFM1 Long R, ZhuY, et al. Therapeutic rold of melatonin in migraine prophylaxis: A systematic review. Medicine (Baltimore). 2019;98(3):e14099.

REFN Neonatal Sepsis

REFN1 Henderson R, Kim S, et al. Use of melatonin as adjunctive therapy in neonatal sepsis: A systematic review and meta-analysis. Complement Ther Med. 2018 Aug;39:131-136.

REFO Parkinson Disease

REFO1 Zhang W, Chen XY, et al. Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol Sci. 2016;37(1):57-65.

REFP Seasonal Affective Disorder

REFP1 Kaminski-Hartenthaler A, Nussbaumer B, et al. Melatonin and agomelatine for preventing seasonal affective disorder. Cochrane Database Syst Rev. 2015;(11):CD011271.

REFQ Secondary Sleep Disorders

REFQ1 Li T, Jiang S, et al. Exogenous melatonin as a treatment for secondary sleep disorders: A systematic review and meta-analysis. Front Neuroendocrinol. 2019 Jan;52:22-28.

REFR Sleep Disorders

REFR1 Ferracioli-Oda E, Qawasmi A, et al. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013 May 17;8(5):e63773.

REFR2 Auld F, Maschauer EL, et al. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017;34:10-22.

REFR3 Abdelgadir IS, Gordon MA, et al. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. Arch Dis Child. 2018 Dec;103(12):1155-1162.

REFS Sleep Disturbances

REFS1 Liira J, Verbeek JH, et al. Pharmacological interventions for sleepiness and sleep disturbances caused by shift work. Cochrane Database Syst Rev. 2014 Aug 12;(8):CD009776.

Revision Information

  • Reviewer: EBSCO NAT Review Board Eric Hurwitz, DC
  • Review Date: 03/2020
  • Update Date: 06/29/2020